{'52WeekChange': 0.18844986,
 'SandP52WeekChange': 0.0644362,
 'address1': '295 Madison Avenue',
 'address2': 'Suite 2400',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.2,
 'askSize': 1200,
 'averageDailyVolume10Day': 455650,
 'averageVolume': 116898,
 'averageVolume10days': 455650,
 'beta': 2.319855,
 'beta3Year': None,
 'bid': 3.8,
 'bidSize': 1200,
 'bookValue': 0.623,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.17,
 'dayLow': 3.8,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.083,
 'enterpriseToRevenue': None,
 'enterpriseValue': 64091308,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.0282857,
 'fiftyTwoWeekHigh': 5.059,
 'fiftyTwoWeekLow': 1.11,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 12419538,
 'forwardEps': -0.96,
 'forwardPE': -4.072917,
 'fromCurrency': None,
 'fullTimeEmployees': 27,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.433,
 'heldPercentInstitutions': 0.05973,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/eyenoviabio.com',
 'longBusinessSummary': 'Eyenovia, Inc., a clinical stage ophthalmic '
                        'biopharmaceutical company, engages in developing a '
                        'pipeline of microdose therapeutics utilizing its '
                        'patented piezo-print delivery technology, branded the '
                        'Optejet. It focuses on achieving clinical microdosing '
                        'of next-generation formulations of ophthalmic '
                        'pharmaceutical agents using its ocular delivery '
                        'system, which has the potential to replace '
                        'conventional eye dropper delivery and improve safety, '
                        'tolerability, patient compliance, and topical '
                        'delivery success for ophthalmic eye treatments. The '
                        'company, through its proprietary delivery technology, '
                        'is developing smart ophthalmic therapies while '
                        'targeting new indications for which there are '
                        'currently no drug therapies approved by the U.S. Food '
                        'and Drug Administration. Eyenovia, Inc. focuses on '
                        'advancing its MicroLine program for the improvement '
                        'in near vision in patients with presbyopia in Phase '
                        'III development. Its other product candidates include '
                        'MicroProst, which is in Phase III clinical trials for '
                        'the treatment of chronic angle closure glaucoma, open '
                        'angle glaucoma, and ocular hypertension; MicroStat, '
                        'which has completed Phase III clinical trials for the '
                        'treatment of mydriasis; MicroTears for the treatment '
                        'of red eye and itch relief lubrication; and MicroPine '
                        'for the treatment of progressive myopia. The company '
                        'was formerly known as PGP Holdings V, Inc. and '
                        'changed its name to Eyenovia, Inc. in May 2014. '
                        'Eyenovia, Inc. was founded in 2014 and is based in '
                        'New York, New York.',
 'longName': 'Eyenovia, Inc.',
 'market': 'us_market',
 'marketCap': 77324160,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_291491698',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -20675284,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.08,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '917-289-1117',
 'previousClose': 4.24,
 'priceHint': 4,
 'priceToBook': 6.2760835,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.17,
 'regularMarketDayLow': 3.8,
 'regularMarketOpen': 4.08,
 'regularMarketPreviousClose': 4.24,
 'regularMarketPrice': 4.08,
 'regularMarketVolume': 349249,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 19776000,
 'sharesPercentSharesOut': 0.0052,
 'sharesShort': 103080,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 166388,
 'shortName': 'Eyenovia, Inc.',
 'shortPercentOfFloat': 0.008,
 'shortRatio': 1.14,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'EYEN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.317,
 'twoHundredDayAverage': 3.3751512,
 'volume': 349249,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.eyenoviabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10017'}